Systematic evaluation and Meta-analysis of Danhuang Quyu capsules in the treatment of chronic pelvic inflammatory disease

doi:10.19803/j.1672-8629.2022.09.15

Abstract

Abstract: Objective To evaluate the efficacy and safety of Danhuang Quyu capsules in the treatment of chronic pelvic inflammatory disease. Methods Eight electronic databases (the Cochrane Library, PubMed, EMBASE, Web of Science, China Biomedical Database Web, China National Knowledge Infrastructure Databases, Chinese Scientific Journal Database, and Wanfang database) were searched for related articles published from inception to August 16, 2021 to retrieve RCTs related to Danhuang Quyu capsules in the treatment of chronic pelvic inflammatory disease. The improved Jadad score was used to assess the quality of literature. The criteria established by Cochrane Handbook 5.3 and RevMan 5.4 software were used for meta-analysis. Results 10 RCTs were included, with a total sample size of 1 411 cases (813 in the experimental group and 598 in the control group). Measures of intervention described in the literature were Danhuang Quyu capsules + conventional antibiotic treatment vs conventional antibiotic treatment, Danhuang Quyu capsules vs proprietary Chinese medicine treatment, and Danhuang Quyu capsules combined with proprietary Chinese medicine treatment vs proprietary Chinese medicine treatment. Meta-analysis showed that the therapeutic effect of Danhuang Quyu capsules was significantly better than in the control group as was evidenced by the disappearance rate of symptoms and signs (RR=1.40, 95%CI [1.13, 1.75], P=0.003), that of pelvic mass (RR=1.55, 95%CI [1.19, 2.03], P=0.001), pelvic mass size (MD=-1.03, 95%CI[-1.29, -0.77], P < 0.000 01) and that of lower abdominal tenderness (RR=1.56, 95%CI[1.18, 2.07], P=0.002) . However, there was no statistically significant difference between Danhuang Quyu capsules combined with conventional antibiotic treatment and treatment with antibiotics alone in the effect of reducing the recurrence rate within one month (RR=1.26, 95%CI [0.95, 1.65],P=0.10). There was no significant difference in the incidence of adverse reactions between the experimental group and the control group. Conclusion Danhuang Quyu capsules alone or combined with the control group are much more effective in mitigating chronic pelvic inflammation than in the control group. Due to the limited amount of the literature, the results of the above research need to be verified by high-quality RCT studies.

Key words: Danhuang Quyu capsule, chronic pelvic inflammation, Meta-analysis, effectiveness, safety

CLC Number:

R978.1

ZHAO Xiaoxiao, LIU Fumei, XI Junyu, SHI Buwen, XIE Yanming, WANG Lianxin. Systematic evaluation and Meta-analysis of Danhuang Quyu capsules in the treatment of chronic pelvic inflammatory disease[J]. Chinese Journal of Pharmacovigilance, 2022, 19(9): 1002-1008.

References

[1] XIE X, GOU WL.Obstetrics and Gynecology[M]. 8th ed. Beijing: People’s Health Publishing House(人民卫生出版社), 2013.
[2] Standardization Project Team of “Guidelines for Clinical Application of Chinese Patent Medicines in Treating Predominant Diseases”. Guidelines for Clinical Application of Chinese Patent Medicines in Treating Sequelae of Pelvic Inflammatory Diseases (2020)[J]. China Journal of Integrated Traditional Chinese and Western Medicine(中国中西医结合杂志), 2021, 41(3): 286-299.
[3] FAN SR, ZHANG HP.2010 US Centers for Disease Control guidelines for the treatment of pelvic inflammatory disease[J]. Chinese General Practice(中国全科医学), 2011, 14(14): 1165-1166.
[4] Ministry of Health of the People’s Republic of China. Guidelines for Clinical Research of New Chinese Medicines: The First Series[S]. Beijing: China Pharmaceutical Science and Technology Press(中国医药科技出版社), 1997: 251-254.
[5] QUAN XJ.Danhuang Quyu capsule combined intravenous drip of antibiotics on pelvic mass size and blood rheology of qi deficiency and blood stasis syndrome of pelvic inflammatory mass[J]. Liaoning Journal of Traditional Chinese Medicine(辽宁中医杂志), 2016, 43(2): 315-317.
[6] HUANG XL.Clinical analysis of Danhuang Quyu capsule combined with antibiotics in the treatment of chronic pelvic inflammatory disease[J]. Journal of North China University of Science and Technology(Health Sciences Edition)(华北煤炭医学院学报), 2011, 13(1): 54-55.
[7] GONG YM, XU CJ. Application of Danhuang Quyu capsule combined with clindamycin in patients with chronic pelvic inflammatory disease and its effect on inflammatory factors[J]. Electronic Journal of General Stomatology(全科口腔医学电子杂志), 2019, 6(24): 160, 165.
[8] CHEN QZ, TIAN QZ, CHEN X.Clinical study on Danhuang Quyu capsule combined with clindamycin in treatment of chronic pelvic inflammation[J], Drugs & Clinic(现代药物与临床), 2017, 32(5): 844-847.
[9] MENG F, CHEN XQ, LI QY, et al.Clinical study on Danhuang Quyu capsules combined with levofloxacin in treatment of chronic pelvic inflammatory disease[J], Drugs & Clinic(现代药物与临床), 2019, 34(2): 464-467.
[10] HUANG YY, Zhang JJ, Xiao HL, et al. Observation on the effect of Danhuang Quyu capsule combined with levofloxacin in the treatment of chronic pelvic inflammatory disease[J]. Chinese Journal of Rural Medicine and Pharmacy(中国乡村医药), 2020, 27(24): 36,40.
[11] CHEN D, KUANG GC, HE TH.Clinical observation of 35 cases of chronic pelvic inflammatory mass treated with Danhuang Quyu capsule[J]. Guiding Journal of Traditional Chinese Medicine and Pharmacy(中医药导报), 2013, 19(11): 100-101.
[12] GAO L, DU Y, YU CL.Observation on the effect of integrated traditional Chinese and Western medicine in the treatment of chronic pelvic inflammatory disease[J]. Journal of Community Medicine(社区医学杂志), 2011, 9(6): 15.
[13] SHANG W, ZHANG LX.Clinical Research on Danhuang Quyu capsule in the treatment of sequelea of pelvic inflammatory disease for the protection of Chinese Materia Medica[J]. World Chinese Medicine(世界中医药), 2017, 12(10): 2362-2366, 2370.
[14] WU YC, ZHANG Y.Study on the effect of Dan Huang Quyu capsule and Kangfu Xiaoyan suppository on reliving chronic pain due to PID and the partial mechanism[J]. World Chinese Medicine(世界中医药), 2015, 10(10): 1522-1524, 1528.
[15] WU WX, LIAO QP.Epidemiology of pelvic inflammatory disease[J]. Journal of Practical Obstetrics and Gynecology(实用妇产科杂志), 2013, 29(10): 721-723.
[16] LIU ZH, CHEN L, LIAO QP.Investigation of the patients hospitalized in domestic seven hospitals with acute pelvic inflammation disease[J]. Chinese Journal of Practical Gynecology and Obstetrics(中国实用妇科与产科杂志), 2009, 25(2): 121-123.
[17] LIU ZH.The overtreatment and inadequate treatment of pelvic inflammatory disease[J]. Chinese Journal of Practical Gynecology and Obstetrics(中国实用妇科与产科杂志), 2011, 27(7): 509-511.
[18] ZHANG YZ.Traditional Chinese Medicine Gynecology[M]. 2nd ed. Beijing: China Traditional Chinese Medicine Press(中国中医药出版社), 2017.
[19] XU MB, LIU YF, CHEN JX, et al.Theoretical study on Xiaojin pills int the treatment of chronic pelvic inflammation[J]. World Chinese Medicine(世界中医药), 2019, 14(9): 2260-2262.
[20] LIU MS, WEN MH, HU XD.A clinical epidemiological study on the regularity of traditional Chinese medicine syndromes in the sequelae of pelvic inflammatory disease[J]. Journal of New Chinese Medicine(新中医), 2011, 43(3): 70-71.
[21] TAN QF, LIN J.A brief analysis of Zhang Xichun’s academic thought of differentiation and treatment of gynecology[J]. Hubei Journal of Traditional Chinese Medicine(湖北中医杂志), 2021, 43(12): 20-23.
[22] LI QX, QIU YX.Clinical effect observation of the quadruple therapy of traditional Chinese medicine on the accumulation and stasis of damp-heat type pelvic inflammation and some mechanisms exploration[J]. World Chinese Medicine(世界中医药), 2018, 13(7): 1689-1692, 1696.
[23] YANG CC, JI XL, WEN Y, et al.Experimental study on Qingre Quyu decoction on inflammatory cytokines and adhesion-associated immunemolecules in rats with chronic pelvic inflammatory disease[J]. World Chinese Medicine(世界中医药), 2021, 16(2): 259-262.
[24] WANG M.Chinese patent medicine treatment of pelvic inflammatory disease sequela clinical application guidelines Literature and questionnaire survey[D]. Chengdu: Chengdu University of Traditional Chinese Medicine(成都中医药大学), 2018.